RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oryzon Genomics Stock

Oryzon Genomics Employees 2024

Oryzon Genomics Employees

43

Ticker

ORY.MC

ISIN

ES0167733015

WKN

A2ACV2

In 2024, Oryzon Genomics employed 43 people, a 0% change from the 43 number of employees in the previous year.

Oryzon Genomics Aktienanalyse

What does Oryzon Genomics do?

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Oryzon Genomics's Employee Base

Oryzon Genomics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Oryzon Genomics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Oryzon Genomics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Oryzon Genomics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Oryzon Genomics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Oryzon Genomics stock

How many employees does Oryzon Genomics have this year?

Oryzon Genomics has 43 undefined employees this year.

How many employees did Oryzon Genomics have compared to the previous year?

Compared to the previous year, Oryzon Genomics had 0% more employees.

What impact did the number of employees have on the company Oryzon Genomics?

The number of employees has a direct impact on the efficiency and productivity of Oryzon Genomics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Oryzon Genomics?

The number of employees can also have an impact on investors of Oryzon Genomics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Oryzon Genomics affect the company?

An increase in equity of Oryzon Genomics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Oryzon Genomics's equity affect the company?

A reduction in equity of Oryzon Genomics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Oryzon Genomics?

Some factors that can influence the equity of Oryzon Genomics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Oryzon Genomics so important for investors?

The equity of Oryzon Genomics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Oryzon Genomics influence the company?

The number of employees at Oryzon Genomics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Oryzon Genomics evolved in recent years?

In recent years, the number of employees at Oryzon Genomics has changed by 0.

How many employees does Oryzon Genomics currently have?

Oryzon Genomics currently has 43 undefined employees.

Why is the number of employees important for investors of Oryzon Genomics?

The number of employees is important for investors of Oryzon Genomics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Oryzon Genomics take to change the number of employees?

To change the number of employees, Oryzon Genomics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Oryzon Genomics pay?

Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Oryzon Genomics?

The current dividend yield of Oryzon Genomics is .

When does Oryzon Genomics pay dividends?

Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oryzon Genomics?

Oryzon Genomics paid dividends every year for the past 0 years.

What is the dividend of Oryzon Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oryzon Genomics located?

Oryzon Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oryzon Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oryzon Genomics from 9/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Oryzon Genomics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Oryzon Genomics in the year 2023?

In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.

In which currency does Oryzon Genomics pay out the dividend?

The dividends of Oryzon Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oryzon Genomics

Our stock analysis for Oryzon Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.